Use of Darifenacin and Mirabegron in patients suffering with urinary urgency

Efficacy, Tolerability and Safety Darifenancin versus Mirabegron versus combined therapy of Darifenancin and Mirabegron in patients with Overactive Bladder

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058295

Enrollment

Registered

2023-10-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N394- Other specified urinary incontinence

Interventions

Intervention1: Darifenancin 7.5 mg twice daily for 3 months: Darifenancin 7.5 mg twice daily for 3 months oral route Control Intervention1: Darifenancin versus Mirabegron versus combined therapy of Da

Eligibility

Inclusion criteria

Inclusion criteria: Age =18yrs Patients having symptoms of OAB

Exclusion criteria

Exclusion criteria: 1 Any disease other than OAB that might affect voiding, 2 Long QT syndrome, serious heart disease, 3 Hypersensitivity to b-agonists or antimuscarinics, 4 Surgical therapy that might affect urinary tract function 5 Patients not giving consent

Design outcomes

Primary

Measure	Time frame
Overactive bladder symptom scoreTimepoint: after 12 weeks	—

Secondary

Measure	Time frame
) To evaluate benefit of add on therapy of mirabegron and darifenancin 2) To evaluate the time taken to achieve 50 % reduction in incontinent episodes Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Jai Bhagwan Sharma

All India Institute of Medical sciences

jbsharma2000@gmail.com9868138205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026